Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5935-5941

  Bible, Keith C ^a   Lensing, Janet L ^a   Nelson, Sacha A ^a   Lee, Yean K ^a   Reid, Joel M ^a,b   Ames, Matthew M ^a,b   Isham, Crescent R ^a   Piens, Jill ^a   Rubin, Stacie L ^a   Rubin, Joseph ^a   Kaufmann, Scott H ^a,b   Atherton, Pamela J ^a   Sloan, Jeffrey A ^a   Daiss, Michelle K ^a   Adjei, Alex A ^a   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; CYCLIN D1; DOXORUBICIN; FLAVOPIRIDOL; PROTEIN MCL 1; PROTEIN P53; RNA POLYMERASE II; STAT3 PROTEIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DNA INTERACTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; SENSORY DYSFUNCTION; SKIN CANCER; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; COHORT STUDIES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAVONOIDS; HUMANS; IMMUNOBLOTTING; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT3 TRANSCRIPTION FACTOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23844536143     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2566     Document Type: Article

References (40)

1. Senderowicz AM, Headlee D, Stinson SF, et al. A phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-99.
2. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
3. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589-95.
4. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol 1993;46:1831-40.
5. Sedlacek HH, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996;9:1143-68.
6. de Azevedo WF, Mueller-Dieckmann H-J, Schulze-Gahmen U, Worland PJ, Sausville E, Kim S-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996;93:2735-40.
7. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-40.
8. Bible KC, Kaufmann SH. Flavopiridol (NSC 649890, L86-8275): a cytotoxic flavone that induces cell death in human lung carcinoma cells. Cancer Res 1996;56:4856-61.
9. Brüsselbach S, Nettelbeck DM, Sedlacek H-H, Müller R. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1998;77:146-52.
10. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998;91:2482-90.
11. Parker BW, Senderowicz AM, Nieves-Neira W, Pommier Y, Sausville EA. DNA fragmentation and apoptosis of lymphoma and prostate cancer cell lines after flavopiridol treatment. Proc Am Assoc Cancer Res 1996;37:398.
12. König A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307-12.
13. Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997;3:1467-72.
14. Parker BW, Kaur G, Nieves-Neira W, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-65.
15. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence upon functional p53. Blood 1998;92:3804-16,
16. Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin dependent kinase inhibitor, suppresses the growth of squamous cell carcinomas of the head and neck by inducing apoptosis. J Clin Invest 1998;102:1674-81.
17. Drees M, Dengler WA, Roth T, et al. Flavopiridol (L86-8275): selective antitumor in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997;3:273-9.
18. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: importance of sequence of administration. Cancer Res 1997;57:3375-80.
19. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527-36.
20. Wu K, Wang C, D'Amico M, et al. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 2002;1:695-706.
21. Cartee L, Maggio SC, Smith R, Sankala HM, Dent P, Grant S. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol Cancer Ther 2003;2:83-93.
22. Blagosklonny MV, Darzynkiewicz Z, Figg WD. Flavopiridol inversely affects p21 (WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol Ther 2002;1:420-5.
23. Motwani M, Li X, Schwartz GK. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Clin Cancer Res 2000;6:924-32.
24. Li W, Fan J, Bertino JR. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001;61:2579-82.
25. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002;16:1331-43.
26. Nguyen DM, Schrump WD, Tsai WS, et al. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J Thorac Cardiovasc Surg 2003;125:1132-42.
27. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003;2:549-55.
28. Nahta R, Trent S, Yang C, Schmidt EV. Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res 2003;63:3626-31.
29. Wright J, Blatner GL, Cheson BD. Clinical trials of flavopiridol. Oncology 1998;12:1018-24.
30. Chao SH, Fupnaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-8.
31. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793-9.
32. Bible KC, Bible RH Jr, Kottke TJ, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000;60:2419-28.
33. Bible KC, Bible RH Jr, Kottke TJ, et al. Flavopiridol binds to Duplex DNA. Proc Am Assoc Cancer Res 2000;41:313.
34. Lee YK, Kaufmann SH, Bible KC. Flavopiridol disrupts transcription factor/DNA binding. Proc Am Assoc Cancer Res 2001;42:908.
35. Bible KC, Boerner SA, Kirkland K, et al. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 2000;6:661-70.
36. Innocenti F, Stadler WM, Iyer L, Ramirez J, Vokes EE, Ratain MJ. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 2000;6:3400-5.
37. Atherton Skaff P, Sloan JA, Anderson RL, et al. An integrated system for monitoring, reporting and analyzing phase I oncology clinical trials. Control Clin Trials 1999;20:913.
38. Licitra EJ, Vyas V, Nelson K, et al. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clin Cancer Res 2003;9:1673-9.
39. Bash-Babula J, Toppmeyer D, Labassi M, et al. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res 2002;8:1057-64.
40. Grant S, Roberts J, Poplin E, et al. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res 1998;4:611-8.